A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington's disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studies.

Trial Profile

A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington's disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Selisistat (Primary)
  • Indications Huntington's disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PADDINGTON
  • Sponsors Siena Biotech
  • Most Recent Events

    • 09 Aug 2017 Last checked against ISRCTN: Current Controlled Trials.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Jan 2012 United Kingdom Clinical Research Network reports accrual to date changed from 1% to 11%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top